NCT07211100Not yet recruiting
Evaluation of the Effectiveness of a Mobile Application Developed for Hemodialysis Patients.
Evaluation of the Impact of a Mobile Application Developed for Hemodialysis Patients on Treatment Adherence, Symptom Management and Clinical Parameters.
Source: ClinicalTrials.gov · Last updated 7 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate the effectiveness of a mobile health application developed for adult patients undergoing hemodialysis treatment. The mobile application includes modules on adherence to medication, diet, and fluid restrictions, symptom management (fatigue, pain, itching), nutrition guidance, exercise recommendations, and motivational content. It also features reminder notifications, an "Ask the Expert" module, and personal symptom tracking. The research will be conducted as a single-center, single-blind, randomized controlled experimental study. Participants will be assigned to intervention and control groups using block randomization. The intervention group will receive the mobile application, while the control group will receive standard care. Assessments will be carried out at baseline (T0), 1st month (T1), and 2nd month (T2). The measurement tools to be used include the End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ), Post-Dialysis Fatigue Scale, 5-D Itch Scale, Visual Analog Scale (VAS) for pain, and the Mobile Application Usability Scale. In addition, clinical parameters such as serum potassium, phosphorus, and albumin will be evaluated. A total of 72 patients (36 intervention, 36 control) will be included in the study. This study aims to assess the impact of a mobile health application on treatment adherence, symptom management, and clinical parameters among hemodialysis patients, and to develop a digital health model that can be integrated into nursing care.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- First submitted
- 29 Sept 2025
- Start date
- 1 Nov 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Saglik Bilimleri Universitesi
- Diseases
- Chronic kidney disease
- NCT number
- NCT07211100
What you commit to
- Study type: Interventional
- Planned participants: 72
- From 1 Nov 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have undergone kidney transplantation or are scheduled for transplantation within the study period.
Other illness
- Patients with cognitive impairment, severe psychiatric disorders, or communication barriers that may interfere with participation.
- Patients with serious comorbid conditions requiring hospitalization (e.g., advanced cancer, severe heart failure).
Other
- Patients with visual or hearing impairments that prevent the use of the mobile application.
- Participation in another interventional clinical trial within the past 3 months.
Who the study is looking for
- Age ≥ 18 years.
- Diagnosed with end-stage renal disease (ESRD).
- Receiving maintenance hemodialysis treatment for at least 3 months.
- Able to use a smartphone and willing to install the mobile health application.
- Voluntarily agreeing to participate in the study and providing written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gumushane State Hospital Coordinator of this site? Confirm its status | Gümüşhane | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.